Asia Pacific Multiple Sclerosis Drugs Market Size Expands at Significant CAGR of 8.65% to Reach USD 6.72 Billion by 2029
Asia-Pacific multiple sclerosis drugs market is flourishing due to the increasing incidence of multiple sclerosis (MS) in the region, growing awareness about MS, advances in treatment options, expanding healthcare infrastructure, and rising healthcare expenditure.